Progestin-only contraception: Injectables and implants

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 28, Issue 6, 2014, Pages 795-806

  Jacobstein, Roy ^a   Polis, Chelsea B ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

depot medroxyprogesterone acetate (DMPA); HIV; hormonal contraception; hormonal implants; injectable contraception; progestin only contraception

Indexed keywords

GESTAGEN; INJECTABLE CONTRACEPTIVE AGENT; CONTRACEPTIVE AGENT; DELAYED RELEASE FORMULATION; DRUG IMPLANT; MEDROXYPROGESTERONE ACETATE; PROGESTERONE DERIVATIVE;

AFRICA SOUTH OF THE SAHARA; ARTICLE; BODY WEIGHT DISORDER; BONE DENSITY; BONE DISEASE; BREAST FEEDING; CONTRACEPTIVE BEHAVIOR; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; FAMILY PLANNING; FEMALE; HEALTH CARE DELIVERY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALIGNANT NEOPLASTIC DISEASE; MATERNAL MORTALITY; MENSTRUATION; MENSTRUATION DISORDER; OBESITY; PATIENT SATISFACTION; PREGNANCY; PRIORITY JOURNAL; PROGESTIN IMPLANT; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); WEIGHT GAIN; CONTRACEPTION; DELAYED RELEASE FORMULATION; DRUG IMPLANT; INTRAMUSCULAR DRUG ADMINISTRATION; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

BREAST FEEDING; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MEDROXYPROGESTERONE ACETATE; PREGNANCY; PROGESTERONE CONGENERS;

EID: 84906056316     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2014.05.003     Document Type: Article

References (98)

1. B. Keith Home-based administration of depo-subQ provera 104™ in the Uniject™ injection system: a literature review 2011 PATH Seattle
2. R.A. Hatcher, J. Trussell, and A.L. Nelson et al. Contraceptive technology 20th ed. 2011 Ardent Media New York
3. ® Levonorgestrel rod implants: a summary of scientific data and lessons learned from programmatic experience 2002 Population Council New York, NY
4. P. Darney, A. Patel, and K. Rosen et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials Fertil Steril 91 2009 1646 1653
5. D. Mansour, E. Mommers, and H. Teede et al. Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial Contraception 82 2010 243 249
6. M.J. Steiner, L.M. Lopez, and D.A. Grimes et al. Sino-implant (II)-A levonorgestrel-releasing two-rod implant: systematic review of the randomized controlled trials Contraception 81 2010 197 201
7. Bayer Schering Pharma Jadelle training manual for family planning 2008 http://www.k4health.org/toolkits/implants/jadelle-training-manual-family- planning [last accessed May 2014]
8. United Nations Commission on life-saving commodities for women and children Contraceptive commodities for women's health 2012 http://www.unfpa.org/ webdav/site/global/shared/images/publications/2012/UN%20Commission- %20FP%20Synthesis-%20Final%2019%20March%202012.pdf [last accessed 06.05.14]
9. J. Trussell Contraceptive failure in the United States Contraception 83 2011 397 404
10. K.I. Black, S. Gupta, and A. Rassi et al. Why do women experience untimed pregnancies? A review of contraceptive failure rates Best Pract Res Clin Obstet Gynaecol 24 2010 443 455
11. A.M. Kaunitz, P.D. Darney, and D. Ross et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density Contraception 80 2009 7 17
12. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report Contraception 28 1983 1 20
13. Merck Sharp, and B.V. Dohme IMPLANON NXT™: reference guide 2013 Merck Sharp and Dohme New Jersey http://www.k4health.org/toolkits/implants/ implanon-nxt-reference-guide [last accessed 06.05.14]
14. Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs and World Health Organization Family planning: a global handbook for providers, 2011 update Baltimore and Geneva 2011 http://www.who.int/ reproductivehealth/publications/family-planning/9780978856304/en/ [last accessed 06.05.14]
15. H.B. Peterson, Z. Xia, and J.M. Hughes et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization Am J Obstet Gynecol 174 1996 1161 1168 discussion 1168-1170
16. J. Jain, A.J. Jakimiuk, and F.R. Bode et al. Contraceptive efficacy and safety of DMPA-SC Contraception 70 2004 269 275
17. L.M. Lopez, D.A. Grimes, and M. Chen et al. Hormonal contraceptives for contraception in overweight or obese women Cochrane Database Syst Rev 4 2013 CD008452
18. J.A. Robinson, and A.E. Burke Obesity and hormonal contraceptive efficacy Women Health 9 2013 453 466
19. I. Sivin, P. Lahteenmaki, and S. Ranta et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants Contraception 55 1997 81 85
20. H. Xu, J.A. Wade, and J.F. Peipert et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women Obstet Gynecol 120 2012 21 26
21. World Health Organization Selected practice recommendations for contraceptive use 2nd ed. 2004 World Health Organization Geneva http://www.who.int/reproductivehealth/publications/family-planning/ 9241562846index/en/ [last accessed 06.05.14]
22. Department of Reproductive Health, World Health Organization Medical eligibility criteria for contraceptive use 4th ed. 2009 WHO Geneva http://www.who.int/reproductivehealth/publications/family-planning/ 9789241563888/en/ [last accessed 06.05.14]
23. J. Stanback, Z. Qureshi, and C. Sekadde-Kigondu et al. Checklist for ruling out pregnancy among family-planning clients in primary care Lancet 354 1999 566
24. K.M. Curtis Centers for Disease Control US selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition MMWR 62 2013 1 60
25. World Health Organization Selected practice recommendations for contraceptive use, 2008 update 2008 World Health Organization Geneva http://whqlibdoc.who.int/hq/2008/WHO-RHR-08.17-eng.pdf?ua=1 [last accessed 06.05.14]
26. J. Stanback, F. Diabate, and T. Dieng et al. Ruling out pregnancy among family planning clients: the impact of a checklist in three countries Stud Fam Plann 36 2005 311 315
27. C.B. Polis, G.F. Nakigozi, and H. Nakawooya et al. Preference for Sayana Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial Contraception 89 5 2014 385 395
28. H.M. Burke, M.P. Mueller, and B. Perry et al. Observational study of the acceptability of Sayana Press among intramuscular DMPA users in Uganda and Senegal Contraception 89 5 2014 361 387
29. V. Halpern, S.L. Combes, and L.J. Dorflinger et al. Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm Contraception 89 2014 31 35
30. M.J. Steiner, C. Kwok, and J. Stanback et al. Injectable contraception: what should the longest interval be for reinjections? Contraception 77 2008 410 414
31. T. Pardthaisong, R.H. Gray, and E.B. McDaniel Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine Devices in Northern Thailand Lancet 315 1980 509 512
32. P.C. Schwallie, and J.R. Assenzo The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function and the return of fertility following its discontinuation: a review Contraception 10 1974 181 202
33. K. Fotherby, S. Yong-En, and G. Howard et al. Return of ovulation and fertility in women using norethisterone oenanthate Contraception 29 1984 447 455
34. J. Jain, C. Dutton, and A. Nicosia et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera Contraception 70 2004 11 18
35. R. Jacobstein, and H. Stanley Contraceptive implants: providing better choice to meet growing family planning demand Global Health Sci Pract 1 2013 11 17 http://dx.doi.org/10.9745/GHSP-D-12-00003 [last accessed 06.05.14]
36. C. Dehlendorf, K. Levy, and A. Kelley et al. Women's preferences for contraceptive counseling and decision making Contraception 88 2013 250 256
37. G. Bachmann, and P. Korner Bleeding patterns associated with non-oral hormonal contraceptives: a review of the literature Contraception 79 2009 247 258
38. E.M. Belsey Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception Contraception 38 1988 181 206
39. D. Mansour, T. Korver, and M. Marintcheva-Petrova et al. The effects of Implanon on menstrual bleeding patterns Eur J ContraceptReprod Health Care 13 Suppl. 1 2008 13 28
40. D. Hubacher, L. Lopez, and M.J. Steiner et al. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons Contraception 80 2009 113 118
41. R.D. Arias, J.K. Jain, and C. Brucker et al. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg Contraception 74 2006 234 238
42. C. Westhoff, J.K. Jain, and I. Milsom et al. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL Contraception 75 2007 261 267
43. D. Mansour, L. Bahamondes, and H. Critchley et al. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users Contraception 83 2011 202 210
44. C. Paul, D.C. Skegg, and S. Williams Depot medroxyprogesterone acetate. Patterns of use and reasons for discontinuation Contraception 56 1997 209 214
45. L.M. Lopez, A. Edelman, and M. Chen et al. Progestin-only contraceptives: effects on weight Cochrane Database Syst Rev 7 2013 CD008815
46. M.E. Beksinska, J.A. Smit, and I. Kleinschmidt et al. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception Contraception 81 2010 30 34
47. H.T. Salem, M. Salah, and M.Y. Aly et al. Acceptability of injectable contraceptives in Assiut, Egypt Contraception 38 1988 697 710
48. Pfizer Inc Depo-subQ provera 104™ medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL: physician onformation 2009 http://labeling.pfizer.com/ShowLabeling.aspx?id=549 [last accessed 06.05.14]
49. Pfizer Inc DEPO-PROVERA CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use: physician information 2012 http://labeling.pfizer.com/ShowLabeling.aspx?id=522 [last accessed 06.05.14]
50. L.M. Lopez, M. Chen, and S. Mullins et al. Steroidal contraceptives and bone fractures in women: evidence from observational studies Cochrane Database Syst Rev 8 2012 CD009849
51. L.M. Lopez, D.A. Grimes, and K.F. Schulz et al. Steroidal contraceptives: effect on bone fractures in women Cochrane Database Syst Rev 2011 CD006033
52. L.L. Lanza, L.J. McQuay, and K.J. Rothman et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture Obstet Gynecol 121 2013 593 600
53. C. d'Arcangues WHO statement on hormonal contraception and bone health Contraception 73 2006 443 444
54. ACOG ACOG Committee Opinion No. 415: depot medroxyprogesterone acetate and bone effects Obstet Gynecol 112 2008 727 730
55. A.M. Kaunitz, and D.A. Grimes Removing the black box warning for depot medroxyprogesterone acetate Contraception 84 2011 212 213
56. A.O. Mueck, H. Seeger, and T. Rabe Hormonal contraception and risk of endometrial cancer: a systematic review Endocr Relat Cancer 17 2010 R263 R271
57. Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer The WHO collaborative study of neoplasia and steroid contraceptives Int J Cancer 49 1991 191 195
58. C.I. Li, E.F. Beaber, and M.T. Tang et al. Effect of depo- medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age Cancer Res 72 2012 2028 2035
59. M. Urban, E. Banks, and S. Egger et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study PLoS Med 9 2012 e1001182
60. Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer The WHO collaborative study of neoplasia and steroid contraceptives Contraception 45 1992 299 312
61. L. Mascarenhas, A. van Beek, and H.C. Bennink et al. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK Hum Reprod 13 1998 3057 3060
62. C. Sweeney, A.R. Giuliano, and K.B. Baumgartner et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women Int J Cancer 121 2007 2517 2523
63. ® Press: results from community health workers and clinic-based providers in Uganda and Senegal Contraception 89 5 2014 368 373
64. N. Ortayli Users' perspectives on implantable contraceptives for women Contraception 65 2002 107 111
65. M.M. Ali, J.G. Cleland, and I.H. Shah Causes and consequences of contraceptive discontinuation: evidence from 60 demographic and health surveys 2012 World Health Organization Geneva [last accessed 06.05.14] http://www.who.int/reproductivehealth/publications/family-planning/ 9789241504058/en/
66. J. Power, R. French, and F. Cowan Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy Cochrane Database Syst Rev 2007 CD001326
67. A.K. Jain, F. Obare, and S. RamaRao et al. Reducing unmet need by supporting women with met need Int Perspect Sex Reprod Health 39 2013 133 141
68. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices Obstet Gynecol 120 2012 983 988
69. World Health Organization. WHO policy brief From evidence to policy: optimizing the health workforce for effective family planning services 2012 WHO Geneva http://apps.who.int/iris/bitstream/10665/75164/1/WHO-RHR-HRP-12.19-eng. pdf [last accessed 06.05.14]
70. ® Press provision in Senegal and Uganda Contraception 89 5 2014 374 378
71. ® Press in Ethiopia: a qualitative study Contraception 89 5 2014 379 384
72. S. Duvall, S. Thurston, and M. Weinberger et al. Scaling up delivery of contraceptive implants in sub-Saharan Africa: operational experiences of Marie Stopes International Glob Health Sci Pract 2 2014 72 92
73. M. Asnake, E.G. Henry, and Y. Tilahun et al. Addressing unmet need for long-acting family planning in Ethiopia: uptake of single-rod progestogen contraceptive implants (Implanon) and characteristics of users Int J Gynaecol Obstet 123 Suppl. 1 2013 e29 32
74. K.H. Rademacher, H.L. Vahdat, and L. Dorflinger et al. Global introduction of a low-cost contraceptive implant Crit Issues Reprod Health 33 2014 285 306
75. K. Tumlinson, M.J. Steiner, and K.H. Rademacher et al. The promise of affordable implants: is cost recovery possible in Kenya? Contraception 83 2011 88 93
76. S.A. Cohen London summit puts family planning back on the agenda, offers new lease on life for millions of women and girls Guttmacher Policy Review 15 2012 http://www.guttmacher.org/pubs/gpr/15/3/gpr150320.html [last accessed 06.05.14]
77. Bill and Melinda Gates Foundation Innovative partnership reduces cost of Bayer's long-acting reversible contraceptive implant by more than 50 percent (press release) 2013 http://www.gatesfoundation.org/Media-Center/Press-Releases/ 2013/02/Partnership-Reduces-Cost-Of-Bayers-Reversible-Contraceptive-Implant [last accessed 06.05.14]
78. ® in the poorest countries (Press Release) 2013 http://www.k4health.org/sites/ default/files/EXTERNAL%20STATEMENT%20FINAL%20May%202013.pdf [last accessed 06.05.14]
79. J. Trussell, A.M. Lalla, and Q.V. Doan et al. Cost effectiveness of contraceptives in the United States Contraception 79 2009 5 14
80. G.M. Secura, J.E. Allsworth, and T. Madden et al. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception Am J Obstet Gynecol 203 2 2010 115e1 115e7
81. United Nations Department of Economic and Social Affairs Population Division World contraceptive use 2011 2011 United Nations New York City http://www.un.org/esa/population/publications/contraceptive2011/ contraceptive2011.htm [last accessed 06.05.14]
82. The DHS Program STATcompiler. Calverton, MD 2012 http://www.statcompiler. com/ [last accessed 06.05.14]
83. R. Jacobstein, C. Curtis, and J. Spieler et al. Meeting the need for modern contraception: effective solutions to a pressing global challenge Int J Gynaecol Obstet 121 Suppl. 1 2013 S9 S15
84. J. Neukom, J. Chilambwe, and J. Mkandawire et al. Dedicated providers of long-acting reversible contraception: new approach in Zambia Contraception 83 2011 447 452
85. M.I. Rodriguez, and A.M. Kaunitz An evidence-based approach to postpartum use of depot medroxyprogesterone acetate in breastfeeding women Contraception 80 2009 4 6
86. M.B. Brito, R.A. Ferriani, and S.M. Quintana et al. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study Contraception 80 2009 519 526
87. National Collaborating Centre for Women's and Children's Health Long-acting and reversible contraception: the effective and appropriate use of long-acting and reversible contraception 2005 RCOG Press London
88. The Society of Gynaecologists and Obstetricians of Canada Canadian contraception consensus, 143 - Part 2 of 3 2004 http://sogc.org/guidelines/ canadian-contraception-consensus-part-3-of-3-replaces-131aug-2003-and-49-sept- 1996/ [last accessed 06.05.14]
89. J.A. Ross, and W.L. Winfrey Contraception use, intention to use and unmet need during the extended postpartum period Int Fam Plan Perspect 27 2001 20 27
90. C.B. Polis, and K.M. Curtis Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence Lancet Infect Dis 13 2013 797 808
91. C.B. Polis, S.J. Phillips, and K.M. Curtis Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence AIDS 27 2013 493 505
92. R. Heffron, D. Donnell, and H. Rees et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study Lancet Infect Dis 12 2012 19 26
93. S.J. Phillips, K.M. Curtis, and C.B. Polis Effect of hormonal contraceptive methods on HIV disease progression: a systematic review AIDS 27 2013 787 794
94. World Health Organization Hormonal contraception and HIV: technical statement Geneva, Switzerland 2012 http://www.who.int/reproductivehealth/topics/ family-planning/hc-hiv/en/ [last accessed 06.05.14]
95. C.B. Polis, D. Westreich, J. Balkus and the 2013 HC-HIV observational analysis meeting The effect of hormonal contraception on HIV acquisition: analytic approaches and challenges in observational data AIDS 27 2013 S35 S43
96. A. Tseng, and C. Hills-Nieminen Drug interactions between antiretrovirals and hormonal contraceptives Expert Opin Drug Metab Toxicol 9 2013 559 572
97. S. Ahmed, Q. Li, and L. Liu et al. Maternal deaths averted by contraceptive use: an analysis of 172 countries Lancet 380 2012 111 125
98. A.R. Butler, J.A. Smith, and C.B. Polis et al. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk AIDS 27 2013 105 113